6
Treatment
Table A2: Immunosuppressive Agents
Immunosuppressive
Agents Dosing Indications
Anakinra (Anti-IL1) 100 mg s.c. once a day Hematological irAEs
Antithymocyte
globulin (ATG)
(Immune depletion)
500 mg on day 1, titrating the dose by
250 mg increments to daily CD2/3
levels (aiming for levels of 50–100/μl)
for a total of 5 days.
Hematological
irAEs, severe cases of
myocarditis
Caplacizumab
(Anti-vWF antibody)
First day: 11 mg IV bolus at least
15 minutes before plasma exchange,
followed by 11 mg SC aer completion
of plasma exchange on day 1
Subsequent days during daily plasma
exchange: 11 mg SC qd following
plasma exchange
Aer plasma exchange period: 11 mg
SC qd for 30 days following last daily
plasma exchange
Aer initial treatment course: If
sign(s) of persistent underlying
disease, treatment may be extended
for a maximum of 28 days
Acquired
thrombotic
thrombocytopenic
purpura
Dupilumab
(Anti-IL-4)
Initial dose of 600 mg (two 300 mg
injections in different injection sites),
followed by 300 mg given every other
week.
Severe pruritic
dermatitis
Eculizumab
(Anti-C5a)
900 mg weekly × 4 doses, 1,200 mg
week 5, then 1,200 mg every two
weeks
HUS
(cont'd)
